Mr. Elad Mark has served as BiondVax’s COO since 2018. He is an executive leader and principal process engineer with over 15 consecutive years of biotechnology industry experience encompassing diverse project stages Mr. Mark brings broad cGMP operational experience in biological process development and production. Prior to joining BiondVax, Mr. Mark led Novartis’s $800 million investment in a biologics facility in Singapore focused on drug substance manufacturing, designed to support both clinical and commercial production of potential new products that include monoclonal antibodies. With Biopharmax and Antero, both global pharmaceutical engineering companies, Mr. Mark successfully led multiple scale up and tech transfer projects in Israel, China, and Singapore